Similarly, Rothschild et al. [34] found no significant association between PD-L1 expression levels and the pathological response or nodal downstaging in NSCLC patients treated with neoadjuvant chemotherapy followed by durvalumab. This evidence concerns the gene CD274 and non-small cell lung carcinoma.